ZTS Stock Analysis — Zoetis
Sector: Healthcare
AI Verdict
Zoetis is cheap for the growth you're getting, but the market is clearly skeptical that its entrenched position will drive a near-term recovery.
Competitive Moat
Zoetis develops and manufactures proprietary animal health medicines and vaccines, benefiting from high regulatory barriers and entrenched relationships with veterinarians and livestock producers. Its broad portfolio and established distribution networks make it difficult for new entrants to displace its products in both companion and livestock animal markets.
Summary
Zoetis is trading at a deep discount after a -51.65% one-year return, with forward earnings growth expected to rebound.
Where It Stands
Zoetis trades at 10.8x next year's earnings versus the healthcare sector median of 22x, with an RSI of 40.8 signaling the stock is cooling after a steep decline.
Key Metrics
- RSI: 40.8 — Neutral
- Trailing P/E: 12.6x
- Forward P/E: 10.8x
- PEG Ratio: 0.84
- Earnings Growth: +0.2%
- Revenue Growth: +0.0%
- Market Cap: $32.0B
- Dividend Yield: 0.02%
- 1-Year Return: -51.65%
- 52-Week High: $161.77
- 52-Week Low: $71.47
Analyst Consensus
13 Buy · 11 Hold · 0 Sell (24 analysts)
Bull Case
Analysts expect 17.0% forward EPS growth while the stock trades at just 10.8x forward earnings, making it cheap for the growth on offer if the moat holds.
Bear Case
If the P/E multiple reverts further or the RSI dips below 35, another 10–20% downside could materialize from already depressed levels.
Catalyst to Watch
Watch for quarterly earnings and new product launches—surprising upside in companion animal segment margins could trigger a rerating.